{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:55:29Z","timestamp":1783468529437,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013395","name":"Sistema Nacional de Investigadores","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003069","name":"National Polytechnic Institute","doi-asserted-by":"publisher","award":["SIP 20241350"],"award-info":[{"award-number":["SIP 20241350"]}],"id":[{"id":"10.13039\/501100003069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.arcmed.2025.103239","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:40:47Z","timestamp":1749447647000},"page":"103239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Increased LDH Remains a Crucial Prognostic Factor in Patients with Multiple Myeloma"],"prefix":"10.1016","volume":"56","author":[{"given":"Ramiro","family":"Espinoza-Zamora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidia Paulina","family":"Zapata-Canto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3267-2331","authenticated-orcid":false,"given":"Lizbeth Deyanir","family":"Aguilera-Urbina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Cruz-Velazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-6484","authenticated-orcid":false,"given":"Elba","family":"Reyes-Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8070-0415","authenticated-orcid":false,"given":"Jorge","family":"Vela-Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2025.103239_bib0001","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2025.103239_bib0002","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2025.103239_bib0003","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from the International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2025.103239_bib0004","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2025.103239_bib0005","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2025.103239_bib0006","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2217\/fon-2020-1225","article-title":"Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed\/refractory multiple myeloma","volume":"17","author":"H\u00e1jek","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.arcmed.2025.103239_bib0007","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.16124","article-title":"Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008\u20132016","volume":"188","author":"Tietsche de Moraes Hungria","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.arcmed.2025.103239_bib0008","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arcmed.2025.103239_bib0009","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arcmed.2025.103239_bib0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10428190601126602","article-title":"Renal failure in multiple myeloma: incidence, correlations, and prognostic significance","volume":"48","author":"Eleutherakis-Papaiakovou","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.arcmed.2025.103239_bib0011","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ajh.21922","article-title":"High-dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma","volume":"86","author":"Bayraktar","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.arcmed.2025.103239_bib0012","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/leu.2012.182","article-title":"The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma","volume":"27","author":"Dimopoulos","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.arcmed.2025.103239_bib0013","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1038\/bcj.2012.37","article-title":"The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies","volume":"2","author":"Kalff","year":"2012","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.arcmed.2025.103239_bib0014","first-page":"1280","article-title":"Deletion of the retinoblastoma gene in multiple myeloma","volume":"8","author":"Dao","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.arcmed.2025.103239_bib0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0165-4608(99)00144-2","article-title":"Multiple myeloma: monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up","volume":"117","author":"Carlebach","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.arcmed.2025.103239_bib0016","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/cells10020336","article-title":"Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications","volume":"10","author":"Cardona-Benavides","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.arcmed.2025.103239_bib0017","doi-asserted-by":"crossref","first-page":"732","DOI":"10.18632\/oncotarget.26589","article-title":"Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit biallelic inactivation of TP53","volume":"10","author":"Ashby","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.arcmed.2025.103239_bib0018","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-019-0191-y","article-title":"Natural history of multiple myeloma with de novo del(17p)","volume":"9","author":"Lakshman","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.arcmed.2025.103239_bib0019","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.arcmed.2025.103239_bib0020","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3109\/0284186X.2015.1043026","article-title":"Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies","volume":"54","author":"Petrelli","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.arcmed.2025.103239_bib0021","doi-asserted-by":"crossref","first-page":"8335","DOI":"10.3892\/mmr.2017.7637","article-title":"LDHA promotes tumor metastasis by facilitating epithelial\u2011mesenchymal transition in renal cell carcinoma","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.arcmed.2025.103239_bib0022","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2174\/138161212799504902","article-title":"Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis, and metastasis","volume":"18","author":"Dhup","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.arcmed.2025.103239_bib0023","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.arcmed.2025.103239_bib0024","doi-asserted-by":"crossref","first-page":"931","DOI":"10.7326\/0003-4819-115-12-931","article-title":"High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma","volume":"115","author":"Dimopoulos","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.arcmed.2025.103239_bib0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.htct.2022.07.005","article-title":"Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life","volume":"45","author":"Lopes","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.arcmed.2025.103239_bib0026","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440925000591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440925000591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:55:11Z","timestamp":1758765311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440925000591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0188440925000591"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2025.103239","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased LDH Remains a Crucial Prognostic Factor in Patients with Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2025.103239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103239"}}